ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's application, delaying ...
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives ...
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On ...
New guidelines help non-medics correctly identify acute allergic reactions requiring epinephrine administration ...
Abstract: Objective: We applied low-intensity focused ultrasound (LIFU) stimulation of the ventrolateral periaqueductal gray (vlPAG) in spontaneously hypertensive rats (SHRs) model to demonstrate the ...
Hosted on MSN
Nasus Pharma highlights transformational 2025 as NS002 intranasal epinephrine program advances and IPO completes
An announcement from Nasus Pharma Ltd. ( (NSRX)) is now available. On December 22, 2025, Nasus Pharma Ltd. released a shareholder letter from CEO Dan Teleman highlighting a transformational year ...
The approval expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care. Epinephrine is a non-selective alpha and beta adrenergic agonist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback